Related Experiment Videos
2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors
P Imbach1, H G Capraro, P Furet
1Novartis Pharmaceuticals, Novartis Limited, Basel, Switzerland.
Bioorganic & Medicinal Chemistry Letters
|February 17, 1999
Abstract:
Novel 2,6,9-substituted purine derivatives represent a class of potent and selective inhibitors of CDK1/cyclinB. The synthesis, SAR and biological profile of selected compounds are described.